Current Edition

cancer

In major shake-up, Novartis combines pharma, oncology units, leaving cancer commercial head, CMO out of job

Novartis CEO Vas Narasimhan is giving the Swiss pharma a huge makeover even ahead of a possible spinoff of generics unit Sandoz, pushing out three …

Continue Reading →
breast

Gilead drops unclear win for key Trodelvy breast cancer trial, poking holes in CEO’s oncology plan

Gilead Sciences has a lot of its oncology ambitions riding on Trodelvy’s success beyond its existing approvals. While investors have been waiting with bated breath …

Continue Reading →
cardiovascular

Daiichi Sankyo, with tighter focus on oncology, sells 8 aging US cardiovascular drugs to diversifying Cosette

With the acquisition of the U.S. sales and distribution rights of eight cardiovascular drugs from Daiichi Sankyo, Cosette Pharma of New Jersey is making a …

Continue Reading →
drugmaker

Ipsen poaches Novartis vet Scheiffele to serve as president of its international specialty care team

Amid its push to grow around the globe in oncology, rare diseases and neuroscience, Ipsen has poached a Novartis veteran to head up its international …

Continue Reading →
biomarker

Recent Advances and Future Challenges Using Biomarkers in Oncology Precision Medicine

Current and future cancer treatment is expected to be shaped and guided by the use of biomarkers that will guide researchers and physicians at every …

Continue Reading →
catalyst

Syneos Health Launches Catalyst Ophthalmology Site Network to Support Faster Start Up and Efficient Trial Delivery

New Network Builds on Success of the Company’s Early Phase, Oncology, Psychiatry and Vaccine Catalyst Site Networks  Syneos Health™ (Nasdaq: SYNH), the only fully integrated …

Continue Reading →
Europe

The University of Texas Md Anderson Cancer Center and Nanobiotix have an agreement to run Immunotherapeutic Pre-Clinical Research in Lung Cancer combining Nbtxr3 and Nivolumab

 NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it will cooperate …

Continue Reading →
enrollment

Nanobiotix presents first promising data from Phase I/II Liver Cancers trial of NBTXR3 at the American Society Of Clinical Oncology Gastrointestinal Annual Meeting

NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces a first readout of …

Continue Reading →
biologics

Tianhe Life Sciences leads $9.5m Series A in Clover Biopharma

Tianhe Life Sciences leads $9.5m Series A in Clover Biopharma Clover is utilising its proprietary Trimer-Tag technology platform to develop biologics targeting trimerization-dependent pathways. Clover …

Continue Reading →
cancer

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting

Nanobiotix, a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, recently presented positive clinical and preclinical data from the ongoing immuno-oncology programs. …

Continue Reading →